| Active substance | Belantamab mafodotin |
| Holder | GlaxoSmithKline Pharmaceuticals S.A./N.V. |
| Status | Running |
| Indication | Belantamab mafodotin is indicated in adults for the treatment of relapsed or refractory multiple myeloma: • in combination with bortezomib and dexamethasone in patients who have had at least one prior therapy; and • in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide |
| Public documents | |
| Last update | 17/11/2025 |